Laccase-Based Biosensor Encapsulated in a Galactomannan-Chitosan Composite for the Evaluation of Phenolic Compounds.

Galactomannan, a neutral polysaccharide, was extracted from carob seeds and characterized. It was used for the first time for the fabrication of a laccase-based biosensor by the encapsulation of laccase in a chitosan+galactomannan composite. The fabricated biosensor was characterized by FTIR, scanning electron microscopy and cyclic voltammetry. The pyrocatechol detection was obtained by cyclic voltammetry measurements, through the detection of o-quinone at -0.447 V. The laccase activity was well preserved in the chitosan+galactomannan composite and the sensitivity of detection of pyrocatechol in the 10-16 M-10-4 M range was very high. The voltammetric response of the biosensor was stable for more than two weeks. To estimate the antioxidant capacity of olive oil samples, it was shown that the obtained laccase-based biosensor is a valuable alternative to the colorimetric Folin-Ciocalteu method.

Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.

OBJECTIVE: To evaluate the efficacy of foscarnet on HIV infection in patients with late-stage HIV disease and multiple drug resistance. METHODS: Three drugs experienced patients with plasma viral load (pVL) > 50,000 copies/ml and CD4+ T-cell counts < 100/mm3 were eligible for this open-label, single-arm, add-on pilot study. Foscarnet induction therapy consisted of 5 g intravenously twice daily for 6 weeks, in addition to a stable antiretroviral regimen. Patients with at least 1 log10 decrease in pVL at week 6 (W6), were given foscarnet 5 g intravenously twice daily on two consecutive days each week. Primary endpoint was the virological response rate at W6. RESULTS: Eleven patients were enrolled with a median baseline pVL at 5.16 log10 copies/ml, median CD4+ T-cell count at 10/mm3 and median number of mutations of 9, 2 and 12 associated with resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTIs and protease inhibitors, respectively. One patient discontinued foscarnet at W2 because of renal toxicity. In an intent-to-treat analysis, the median change in pVL from baseline was -1.99 log10 copies/ml at W2 and -1.79 log10 copies/ml at W6. Eight out of eleven patients had a fall in pVL of at least 1 log10 at W6, and six started maintenance therapy. The median fall in pVL after 12 weeks of maintenance therapy was -0.85 log10 copies/ml in the four patients who reached W12, and the median increase of CD4+ T-cell count was 60/mm3. CONCLUSION: In patients with HIV mutations conferring resistance to all antiretroviral drug classes, foscarnet markedly reduced plasma HIV load and improved immunological status.